Skip to main content
Premium Trial:

Request an Annual Quote

SynX Shareholders, Ontario Court Okay Nanogen Acquisition

NEW YORK, April 20 (GenomeWeb News) - Nanogen of San Diego and Toronto-based SynX Pharma said today that the Ontario Superior Court of Justice and SynX shareholders have approved Nanogen's all-stock transaction of SynX, which was originally announced in February.

The transaction, valued at approximately CA$16.3 million (US$12 million), is currently scheduled for tomorrow, April 21, 2004, but is still "subject to other regulatory approvals and other customary closing conditions," the companies said.

SynX said that it has approximately 11.4 million shares and share equivalents outstanding, and that it expects each of its shareholders to receive approximately CA$1.426 per SynX share in Nanogen common stock.

The exchange ratio will be determined on the closing date, at which time Nanogen will acquire CA$3.5 million in subordinated secured debentures of SynX in exchange for shares of Nanogen stock.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.